The influence of extracellular folate concentration on cellular levels of the folate transport protein and its soluble product was studied directly in cultured human nasopharyngeal carcinoma (KB) cells. As determined by radioimmunoassay, levels of the folate transport protein and the soluble folate-binding protein were 58±17 (mean±SD) and 5±2 pmol/mg cell protein, respectively, in KB cells maintained in standard medium (containing 2,300 nM folic acid). These levels significantly increased to 182±34 and 26±6 pmol/mg cell protein, respectively, in KB cells serially passaged in low folate medium (containing 2-10 nM 5-methyltetrahydrofolate). Increases in folate-binding protein levels occurred more rapidly in KB cells serially passaged in very low folate medium containing < 2 nM folate and were prevented by the addition of 100 nM 5-methyltetrahydrofolate or 0.1-1 ;&M 5-formyltetrahydrofolate to this medium. When KB cells which had been passaged in low folate medium were passaged back into either standard medium or low folate medium supplemented with reduced folates, the levels of both folate-binding proteins fell linearly towards the levels in KB cells continuously maintained in standard medium. The folate transport protein was identified in and underwent similar changes in human and mouse mammary tumor cells. These studies indicate that the folate transport system is probably regulated by the extracellular folate concentration through changes in intracellular metabolite levels.
Introduction
High-affinity folate-binding proteins (FBP)' have been identified in and purified from a number ofmammalian and human sources . Recently the membrane-associated FBP of cultured human epidermoid carcinoma (KB) cells was shown to be involved in 5-methyltetrahydrofolate and folic acid (PteGlu) transport in intact cells (20) . This membrane-associated FBP also bound large quantities of the chemotherapeutically active folate analogue, methotrexate, in KB cells grown in a physiologic concentration and form of folate (26) , suggesting a role for this folate transport protein in methotrexate transport and/or storage.
Soluble FBPs have been found in serum (2, 17) , milk (1, 2, 8, 13, 16) , specific granules of leukocytes (3, 4, 10, 17) , and human spleen (25). Human lymphocytes in culture (18) and KB cells (22) (23) (24) released soluble FBP into their growth medium. The KB cell soluble FBP was immunologically crossreactive with KB cell folate transport protein (22) (23) (24) , as well as human placental folate receptor and human milk folate binding proteins (22, 23) . Several functions have been suggested for soluble FBP, but none has been proven (3, 6, 9, 13, 20, (27) (28) (29) (30) (31) (32) (33) (34) .
A precursor-product relationship between the cell-associated folate transport protein and the soluble FBP released by human KB cells has recently been demonstrated by pulsechase studies (22) . Both proteins were purified to homogeneity and have been more thoroughly biochemically characterized as glycoproteins, with the folate transport protein exhibiting considerable hydrophobicity (23) , consistent with its membrane location and transport function.
Levels of membrane-associated receptors and transport proteins may be upregulated or downregulated depending upon the availability oftheir effector molecules (35, 36) . Thus, the levels ofthe folate transport protein and its soluble product could be affected by the availability of the effector molecules (folates) to the cell. The effects of extracellular folate concentration and cellular folate content on levels of folate transport protein and soluble FBP have not been studied directly. However, in KB cells cultured in growth medium containing a low folate concentration (3-10 nM): (a) the amount of [3H]PteGlu which bound to acid-washed particulate membrane preparations was increased (30) ; (b) the amount of folate specifically accumulated by intact KB cells was increased 10-40-fold (19, 20) ; (c) the amount of methotrexate specifically accumulated increased fivefold (26) ; and (d) the amounts of cell-associated folate transport protein and its product increased as measured by [3H] PteGlu binding (24) compared with KB cells cultured in standard medium (2,300 nM folic acid). Increased specific binding and uptake of 5-CH3H4 PteGlu by folate-deficient cultured monkey kidney MA 104 cells was also recently reported (21) . The amount ofradioactive PteGlu taken up by the livers of folated-deprived rats was also increased (37) . Conversely, the lack of folate binding in Lactobacillus casei cul-repression ofthe FBP by the presence of high folate levels (38) . Although these studies suggested changes in the levels ofFBPs, the results could not distinguish between changes in the number of available binding sites and changes in actual amounts of FBP since quantitation relied on ligand binding or uptake. Thus, these results could suggest upregulation of the FBPs when the true quantity of FBPs was unchanged. Furthermore, downregulation in high folate medium could appear to occur but merely be the result of incomplete removal of endogenous ligand.
Using a radioimmunoassay (RIA), daCosta and co-workers found that compared to sera of healthy humans, the level of soluble FBP was increased in sera of individuals with a variety of conditions including folate deficiency (12, 39) . However, the cellular folate transport protein was not measured in these studies, and it was unknown whether the increased level of soluble FBP in the sera of these subjects was a reflection of increased synthesis ofsoluble FBP, altered clearance of soluble FBP, or both.
Since standard commercially available tissue culture media contain supraphysiologic levels of folate, we wondered whether FBP levels observed in cells cultured in standard media might be artifactually different from levels in cells cultured in medium containing more physiologic levels of folate. In the present study, the changes in the levels of folate transport protein and soluble FBP in KB cells exposed to standard and specially prepared media containing different extracellular folate concentrations and forms were studied. Initially, folate transport protein and soluble FBP were quantified by [3H]-PteGlu binding. However, to eliminate the ambiguity possibly introduced by using radioactive folate binding to quantify FBP levels, an RIA was constructed to measure each FBP directly. Small quantities of folate transport protein and soluble FBP were purified from KB cells and their conditioned medium, respectively, the latter was radiolabeled, and both were utilized as standards in developing the RIAs. This is the first study to directly determine the effect of extracellular folate concentrations on the levels of the immunoreactive folate transport protein and its product, soluble FBP, in a defined system. Propagation of KB cells. KB cells were propagated as previously described (20, (22) (23) (24) Gelfiltration analysis. Cells were solubilized in Triton X-100 and analyzed by Sephacryl S-200 gel filtration chromatography as previously described (22, 23) .
Methods
Purification offolate transport protein and soluble FBP. KB cell folate transport protein and soluble FBP from KB cell-conditioned medium were purified as previously described (22, 23 (13, 14, 19, 20, (22) (23) (24) filter. Thus, this compartmentation simplified analysis of the levels of cell-associated folate transport protein in the KB cells and soluble FBP in their conditioned medium since the two proteins did not need not to be separated from each other prior to assay, except as described above (22) . As shown in Fig. 1 A, Fig, 3 , > 95% of the 1251I-labeled soluble FBP was precipitable with increasing amounts of the monospecific antiserum to the purified placental folate receptor (14) while < 5% was precipitable with control serum.
Standard curves using the purified KB cell folate transport protein or soluble FBP were linear over a 10-fold range (0.5-5 pmol) as shown in Fig. 4 . Close structural relationship between the cell-associated folate transport protein and soluble FBP is illustrated by their virtually identical immunologic cross-reactivity with the human placental folate receptor antiserum ( 14) in the standard curve for the RIA. (mean±SD, n = 19) pmol/mg cell protein compared with 58±17 pmol/mg cell protein (n = 12) for KB cells maintained in SMEM for a similar number of passages (P < 0.00 1). The soluble FBP levels were 26±6 pmol/mg cell protein (n = 8) and 5±2 pmol/mg cell protein (n = 3) for conditioned media ofKB cells cultured more than 20 passes in LMEM or SMEM, respectively (P < 0.001). As shown in Fig. 5 A, were obtained on conditioned media analyzed at 48 h after cell plating. The effect on FBP levels of returning KB cells grown for more than 30 passes in LMEM into SMEM was investigated. In these KB cells, the folate transport protein and soluble FBP levels linearly fell to 1 10 and 15 pmol/mg cell protein, respectively, after 19 passes back into SMEM as shown in Fig. 5 B. Extrapolation ofthe linear decreases in folate transport protein and soluble FBP suggested that 30-40 passes into high PteGlu medium would be required for the FBPs to return to control levels.
Fig. 5 C shows that folate transport protein and soluble FBP rose more rapidly in KB cells cultured in LMEM-D, but the degree of increase was the same as in KB cells cultured in LMEM. Further passage of these KB cells into LMEM-D containing added reduced folates (100 nM 5-CH3H4PteGlu or 0.1-1 tM 5-CHOH4PteGlu) resulted in a rapid return offolate transport protein and soluble FBP to the same levels as those present in cells cultured in SMEM-D (Fig. 5 D) . Furthermore, the addition of 100 nM 5-CH3H4PteGlu or 0.1-1 gM 1402 Kane et al. . This data indicates that the threshold concentration which results in FBP increases is > 10 nM (as in LMEM), but < 100 nM for 5-CH3H4 PteGlu or 5-CHOH4 PteGlu, since these additions to LMEM-D prevented the increases in FBPs observed for cells cultured in LMEM (10 nM folate) or LMEM-D (< 2 nM folate). Since racemic mixtures of the reduced folates were used in these experiments, the possible relative efficacy and thresholds for the D and L isomers cannot be stated. As noted above, the maximum levels of FBP observed were the same under both of these latter conditions, but the increases occurred more rapidly in LMEM-D, just as the intracellular folate concentration dropped more rapidly. After the initial passage into SMEM-D, small increases in both the folate transport protein (to 90 pmol/mg protein) and soluble FBP (to 10 pmol/mg protein) occurred. These changes appeared to be due to the removal of nonfolate compounds by the dialysis of fetal calf serum since the levels of folate transport protein and soluble FBP remained stable thereafter as KB cells were serially passaged through SMEM-D.
Similar quantitative changes in folate transport protein levels were obtained in other cultured cells as well. Human T47D mammary tumor cells, normal human fibroblasts, normal human lymphocytes, and mouse alpha mammary tumor cells contained a membrane-associated high affinity FBP which could be solubilized with Triton X-100 and eluted with Mr = 160,000 when analyzed by S200 gel filtration chromatography, identical with the results of the human KB cell folate transport protein (19, 20, 22, 23) . In T47D cells, > 95% ofthis folate transport protein could be immunoprecipitated with chicken antiserum to the human placental folate receptor (14) (< 5% precipitated with chicken control serum). The level of this FBP progressively increased from 7.1 pmol/mg cell protein in T47D cells cultured in SMEM-D to 22.6 pmol/mg cell protein after five serial passages into LMEM-D. Similarly, immunoreactive FBP increased six-fold in mouse alpha mammary cells and two-to four-fold in their medium after nine passes in low folate medium. Thus, the upregulation of the folate transport protein in cells exposed to a low extracellular folate concentration was not a unique property of human KB cells.
Discussion
Slowing of the growth rate and increase in cell size of KB cells grown in LMEM or LMEM-D after five to six serial passes in these media correlated with the rapid drop in cellular folate content to 1 pmol/106 cells and 0.3 pmol/106 cells, respectively. Recovery ofgrowth rates to those ofcells in SMEM and SMEM-D, respectively, was accompanied by an increase in both the cell-associated folate transport protein and the soluble FBP. The rate of FBP increase was more rapid in KB cells passaged in LMEM-D, which contained folate levels lower than those reported for normal nonhepatic tissues. The slower rate of increase in folate transport protein in the KB cells serially passaged in LMEM reflected their more adequate folate content secondary to their higher extracellular folate con- centration.
An increase in cellular folate content above 1 pmol/106 cells did not accompany the increase in folate transport protein, however. Several properties of the folate-FBP system may explain this. First, folate transport protein and soluble FBP levels in "control" KB cells cultured in the very high PteGlu levels in SMEM and SMEM-D may be artifactually low compared with the normal physiologic situation due to downregulation as a result of the extremely high intracellular folate levels. Secondly, although cell-associated folate transport protein appears to be involved in folate uptake by cells, -60% of the total cell-associated folate transport protein is insensitive to trypsin and appears to be intracellular. This intracellular portion has been postulated to play a role in intracellular folate availability and retention of folates by cells, and its upregulation may result in more efficient intracellular folate utilization. Thirdly, the intracellular folate levels necessary for normal cellular metabolism in nonhepatic tissues appear to be on the order of 1 pmol/ 106 cells, much lower than in the "control" cells.
Thus Pulse-chase studies of the FBPs of KB cells indicate that folate transport protein is the precursor of soluble FBP (22) . That soluble FBP levels rose and fell as did those of folate transport protein, as well as the essentially identical immunoreactivities of these two proteins observed in the RIA, is consistent with this precursor-product relationship. This evidence suggests that the soluble FBP in human serum may arise from the cellular folate transport protein in a similar manner, and this point deserves further study.
Since the RIA measured both apo-and holo-FBP equally, the possibility ofincorrect results due to interference by endogenous folates that may be obtained when ligand binding or uptake is used to quantify FBPs, especially in cells cultured in medium containing high folate levels, was avoided. The slowing of growth rates, marked increases in both the folate transport protein and soluble FBP in KB cells grown in LMEM (< 10 nM folate), and the more rapid increases in KB cells grown in LMEM-D (< 2 nM folate) suggested that these proteins are extremely important in cellular folate acquisition.
These increases may have allowed the KB cells to adapt to the lower extracellular folate concentration.
Prevention of changes in folate transport protein and soluble FBP levels by the addition of reduced folates to LMEM-D, as well as rapid decreases in folate transport protein and soluble FBP that occurred after the addition of reduced folates to the growth media, indicated that it was the folates, and not some other dialyzable factor in FBS, that were key determinants of the cellular changes leading to upregulation and downregulation of the folate transport system. In KB cells maintained in SMEM or SMEM-D, the great excess of cellular folates over folate transport protein indicated a high degree of saturation with endogenous ligand, whereas folate transport protein was present in great excess over cellular folates in KB cells serially passed in LMEM or LMEM-D. The actual intracellular form(s) of folate, or specific metabolites requiring folate coenzymes for their synthesis or conversion, which stimulate the intracellular mechanism for folate transport protein upregulation have not been identified in these studies. Also, the mechanism by which the increases took place, e.g., gene amplification, increased rate of transcription or translation, reduced rate of degradation, remain to be elucidated, although karyotypes of KB cells adapted to LMEM for 19 passes contained no double minute chromosomes or homogeneous staining regions and could not be distinguished from KB cells maintained in SMEM.
Thus, these results clearly demonstrate for the first time in the same cell system that levels of immunoreactive soluble FBP and the folate transport protein, and not simply binding sites, were influenced by extracellular folate concentration. In addition, similar results were obtained not only with KB cells, but with cultured human and mouse mammary tumor cells. The importance of these proteins in cellular folate metabolism seems unequivocal. Further investigations are underway using the KB cell model system, as well as other human sources of cells, to define the subcellular distribution of the folate transport protein, the function of the soluble FBP, the biochemical relationship of these two proteins, and the metabolic controls and molecular mechanisms of their regulation.
